Guggenheim analyst Vamil Divan lowered the firm’s price target on Valneva (VALN) to $15 from $17 and keeps a Buy rating on the shares. The firm’s lower target is mainly due to lowering its Ixchiq estimates given that product’s slow launch, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Positive Outlook for Valneva Driven by Promising Vaccine Developments and Market Opportunities
- Valneva SE Reports Strong 2024 Financial Performance
- Valneva SE Reports Strong 2024 Financial Results and Positive Outlook for 2025
- Is VALN a Buy, Before Earnings?
- Valneva SE to Present at Key Healthcare Investor Conferences